%PDF-1.4
%
53 0 obj
<>
endobj
50 0 obj
<>
endobj
118 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-03-05T12:15:14Z
2024-03-28T22:06-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T22:06-07:00
application/pdf
Heather
2002-216.april
uuid:6f8e67df-1dd2-11b2-0a00-e00927bd3700
uuid:6f8e67e2-1dd2-11b2-0a00-5b0000000000
endstream
endobj
39 0 obj
<>
endobj
40 0 obj
<>
endobj
54 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
26 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
29 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
32 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
152 0 obj
[156 0 R]
endobj
153 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(patients with early rheumatoid arthritis. J Rheumatol )Tj
0 Tc 0 Tw 0 -1.25 TD
(1999;26:2324-31.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )17.7 (The )54.8 (American College of)]TJ
2.175 -1.25 Td
(Rheumatology preliminary definition of improvement in )Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1995;38:727-35.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Felson D, )54.8 (Anderson J, Boers M, et al. )54.8 (American College of)]TJ
2.175 -1.25 Td
(Rheumatology core set of disease activity measures for use in)Tj
T*
[(rheumatoid arthritis clinical trials. )54.8 (Arthritis Rheum 1993;36:729-40.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Fleiss JL. )17.7 (The design and analysis of clinical experiments. New)]TJ
2.175 -1.25 Td
[(Y)99.8 (ork: John )17.8 (W)39.8 (iley and Sons; 1986.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Bland D, )54.8 (Altman M. Statistical methods for assessing agreement)]TJ
2.175 -1.25 Td
(between two methods of clinical measurement. Lancet 1986;)Tj
0 Tc 0 Tw T*
(1:307-10.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.2375 Td
[(21.)-875.1 (Fries JF)79.7 (, Bloch DA, Sharp JT)73.9 (, et al. )54.8 (Assessment of radiographic)]TJ
2.175 -1.2375 Td
[(progression in rheumatoid arthritis. )54.8 (A)-220.1 (randomized controlled trial.)]TJ
0 -1.2375 TD
(Arthritis Rheum 1986;29:1-9.)Tj
-2.175 -1.2375 Td
[(22.)-875.1 (Menninger H, Meixner C, S\232ndgen )17.7 (W)91.8 (. Progression and repair in)]TJ
2.175 -1.2375 Td
(radiographs of hands and forefeet in early rheumatoid arthritis. )Tj
T*
(J Rheumatol 1995;22:1048-54.)Tj
30.825 22.425 Td
[(23.)-875.1 (Plant MJ, Saklatvala J, Bor)17.7 (g )54.8 (AA, Jones PW)91.7 (, Dawes PT)73.9 (.)]TJ
2.175 -1.2375 Td
(Measurement and prediction of radiological progression in early)Tj
T*
(rheumatoid arthritis. J Rheumatol 1994;21:1808-13.)Tj
-2.175 -1.2375 Td
[(24.)-875.1 (van der Heijde DMFM, van Leeuwen MA, van Riel P)110.7 (, et al.)]TJ
2.175 -1.2375 Td
(Biannual radiographic assessments of hands and feet in a three-year)Tj
T*
(prospective follow-up of patients with early rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1992;35:26-34.)Tj
-2.175 -1.2375 Td
[(25.)-875.1 (Scott DL, Coulton BL, Propert )54.8 (AJ. Long term progression of joint)]TJ
2.175 -1.2375 Td
[(damage in rheumatoid arthritis. )54.8 (Ann Rheum Dis 1986;45:373-8.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (van der Heijde DM, Landewe RB, Lipsky PE, Maini RN,)]TJ
2.175 -1.25 Td
[(A)110.8 (TTRACT)-257.3 (Investigators. Radiological progression rate at baseline)]TJ
0 -1.25 TD
[(predicts treatment dif)17.7 (ferences; results from the )54.8 (A)110.8 (TTRACT)-257.3 (trial)]TJ
T*
[([abstract]. )54.8 (Arthritis Rheum 2001;44 Suppl:S80.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Landewe RB, van der Heijde DM, )17.7 (V)110.8 (erhoeven )54.8 (A, Boonen )54.8 (A, Boers)]TJ
2.175 -1.25 Td
(M, van der Linden S. Radiological progression rate at baseline)Tj
T*
[(predicts treatment dif)17.7 (ferences; results from the COBRA)-220.2 (trial)]TJ
T*
[([abstract]. )54.8 (Arthritis Rheum 2001;44 Suppl:S371.)]TJ
ET
0 0 0 0 scn
408 770 150 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Paulus, et al: Pr)36.8 (ogr)36.8 (ession of radiographic damage)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(713)Tj
ET
0 0 0 0 scn
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
/GS1 gs
420 777 137 -27 re
f*
BT
0 0 0 1 scn
/T1_2 1 Tf
-0.00011 Tc 20.37 0 0 21 460.9631 760.6089 Tm
(\002\003\003\002\004\002\005\006\004\))Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
66 0 obj
<>
endobj
59 0 obj
<>
endobj
58 0 obj
<>
endobj
99 0 obj
<>
endobj
123 0 obj
<>
endobj
62 0 obj
<>
endobj
61 0 obj
<>
endobj
57 0 obj
<>stream
H\N0E
/AZʦQ`&N8.{|g,29cdw{?,*{ S{pw.uNWdT7KڎvVY|:/n~R*{KRW/.n_}й0zytҪiTU{]ҿWsJ:wm'5F9}2˽n"0\tn r\ (rP"2 *J@P#sEF梫
2]ʈ|h[l;
dGG@:f.`$>J씠GU@TG c$>
$>*^*H|^*(X@
*(B
J>㠂T(1@5nG`/5PaH6PaGb¤vǙ:5(@ا?
yB<|<~